**Table e-1. Demographics and clinical features of the patients to whom the COVID-19 questionnaire was emailed, as of May 21, 2020**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Responders**  **(n = 407)** | **Non-responders**  **(n = 179)** | ***p* Value** |
| **Female, n (%)** | 273 (67.1) | 127 (71) | 0.353 |
| **Age at survey, y, median (range)** | 48 (19-86) | 51 (20-84) | 0.053 |
| **MS type, n (%)**  **RRMS**  **SPMS**  **PPMS**  **CIS** | 341 (83.7)  36 (8.8)  25 (6.1)  5 (1.3) | 129 (72.1)  25 (13.9)  23 (12.8)  2 (1.1) | 0.007 |
| **Disease duration, y , mean (SD)** | 15.1 (9.6) | 15.3 (10) | 0.807 |
| **Annualized relapse rate, mean (SD)** | 0.4 (0.6) | 0.3 (0.3) | 0.082 |
| **Last EDSS score, median (range)** | 2.0 (0-8.0) | 2.0 (0-8.5) | 0.029 |
| **Disease modifying treatment, n (%)**  **Interferon beta**  **Glatiramer acetate**  **Dimethylfumarate**  **Teriflunomide**  **Ocrelizumab**  **Rituximab**  **Ofatumumab**  **Natalizumab**  **Fingolimod**  **Alemtuzumab**  **Cladribine**  **Ponesimod**  **Azathioprine** | 304 (74.7)  66 (21.6)  41 (13.4)  60 (19.6)  35 (11.4)  13 (4.3)  21 (6.9)  2 (0.7)  15 (4.9)  36 (11.8)  5 (1.6)  7 (2.3)  2 (0.7)  1 (0.3) | 104 (58.1)  24 (23.1)  26 (25.0)  14 (13.5)  12 (11.5)  5 (4.8)  12 (11.5)  0  0  11 (10.6)  0  0  0  0 | <0.001  0.067 |